Literature DB >> 22437938

Coordinated regulation of myeloid cells by tumours.

Dmitry I Gabrilovich1, Suzanne Ostrand-Rosenberg, Vincenzo Bronte.   

Abstract

Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and are a collection of distinct cell populations with many diverse functions. The three groups of terminally differentiated myeloid cells - macrophages, dendritic cells and granulocytes - are essential for the normal function of both the innate and adaptive immune systems. Mounting evidence indicates that the tumour microenvironment alters myeloid cells and can convert them into potent immunosuppressive cells. Here, we consider myeloid cells as an intricately connected, complex, single system and we focus on how tumours manipulate the myeloid system to evade the host immune response.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22437938      PMCID: PMC3587148          DOI: 10.1038/nri3175

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  201 in total

1.  IL-12 rapidly alters the functional profile of tumor-associated and tumor-infiltrating macrophages in vitro and in vivo.

Authors:  Stephanie K Watkins; Nejat K Egilmez; Jill Suttles; Robert D Stout
Journal:  J Immunol       Date:  2007-02-01       Impact factor: 5.422

2.  CCL2/CCR2 pathway mediates recruitment of myeloid suppressor cells to cancers.

Authors:  Bo Huang; Zhang Lei; Jie Zhao; Wei Gong; Jinwen Liu; Zhenyong Chen; Yi Liu; Dong Li; Ye Yuan; Gui-Mei Zhang; Zuo-Hua Feng
Journal:  Cancer Lett       Date:  2007-01-25       Impact factor: 8.679

3.  Development of plasmacytoid and conventional dendritic cell subtypes from single precursor cells derived in vitro and in vivo.

Authors:  Shalin H Naik; Priyanka Sathe; Hae-Young Park; Donald Metcalf; Anna I Proietto; Aleksander Dakic; Sebastian Carotta; Meredith O'Keeffe; Melanie Bahlo; Anthony Papenfuss; Jong-Young Kwak; Li Wu; Ken Shortman
Journal:  Nat Immunol       Date:  2007-10-07       Impact factor: 25.606

4.  Identification of clonogenic common Flt3+M-CSFR+ plasmacytoid and conventional dendritic cell progenitors in mouse bone marrow.

Authors:  Nobuyuki Onai; Aya Obata-Onai; Michael A Schmid; Toshiaki Ohteki; David Jarrossay; Markus G Manz
Journal:  Nat Immunol       Date:  2007-10-07       Impact factor: 25.606

5.  Dendritic cells infiltrating human non-small cell lung cancer are blocked at immature stage.

Authors:  Ivan Perrot; Dominique Blanchard; Nathalie Freymond; Sylvie Isaac; Benoît Guibert; Yves Pachéco; Serge Lebecque
Journal:  J Immunol       Date:  2007-03-01       Impact factor: 5.422

6.  Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine.

Authors:  Paola Filipazzi; Roberta Valenti; Veronica Huber; Lorenzo Pilla; Paola Canese; Manuela Iero; Chiara Castelli; Luigi Mariani; Giorgio Parmiani; Licia Rivoltini
Journal:  J Clin Oncol       Date:  2007-06-20       Impact factor: 44.544

Review 7.  Altered macrophage differentiation and immune dysfunction in tumor development.

Authors:  Antonio Sica; Vincenzo Bronte
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

8.  Prostaglandin E2 promotes tumor progression by inducing myeloid-derived suppressor cells.

Authors:  Pratima Sinha; Virginia K Clements; Amy M Fulton; Suzanne Ostrand-Rosenberg
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

9.  Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis.

Authors:  Yuhuan Zheng; Zhen Cai; Siqing Wang; Xiang Zhang; Jianfei Qian; Sungyoul Hong; Haiyan Li; Michael Wang; Jing Yang; Qing Yi
Journal:  Blood       Date:  2009-08-26       Impact factor: 22.113

10.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion.

Authors:  Carolyn E Clark; Sunil R Hingorani; Rosemarie Mick; Chelsea Combs; David A Tuveson; Robert H Vonderheide
Journal:  Cancer Res       Date:  2007-10-01       Impact factor: 12.701

View more
  1472 in total

1.  Improved Multiplex Immunohistochemistry for Immune Microenvironment Evaluation of Mouse Formalin-Fixed, Paraffin-Embedded Tissues.

Authors:  Noah Sorrelle; Debolina Ganguly; Adrian T A Dominguez; Yuqing Zhang; Huocong Huang; Lekh N Dahal; Natalie Burton; Arturas Ziemys; Rolf A Brekken
Journal:  J Immunol       Date:  2018-12-03       Impact factor: 5.422

2.  STING Activation Reverses Lymphoma-Mediated Resistance to Antibody Immunotherapy.

Authors:  Lekh N Dahal; Lang Dou; Khiyam Hussain; Rena Liu; Alexander Earley; Kerry L Cox; Salome Murinello; Ian Tracy; Francesco Forconi; Andrew J Steele; Patrick J Duriez; Diego Gomez-Nicola; Jessica L Teeling; Martin J Glennie; Mark S Cragg; Stephen A Beers
Journal:  Cancer Res       Date:  2017-05-16       Impact factor: 12.701

Review 3.  Exploiting the curative potential of adoptive T-cell therapy for cancer.

Authors:  Christian S Hinrichs; Steven A Rosenberg
Journal:  Immunol Rev       Date:  2014-01       Impact factor: 12.988

4.  Absence of host NF-κB p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization.

Authors:  Theresa Barberi; Allison Martin; Rahul Suresh; David J Barakat; Sarah Harris-Bookman; Charles G Drake; Michael Lim; Alan D Friedman
Journal:  Cancer Immunol Immunother       Date:  2018-07-21       Impact factor: 6.968

5.  The Unfolded Protein Response Mediator PERK Governs Myeloid Cell-Driven Immunosuppression in Tumors through Inhibition of STING Signaling.

Authors:  Eslam Mohamed; Rosa A Sierra; Jimena Trillo-Tinoco; Yu Cao; Patrick Innamarato; Kyle K Payne; Alvaro de Mingo Pulido; Jessica Mandula; Shuzhong Zhang; Paul Thevenot; Subir Biswas; Sarah K Abdalla; Tara Lee Costich; Kay Hänggi; Carmen M Anadon; Elsa R Flores; Eric B Haura; Shikhar Mehrotra; Shari Pilon-Thomas; Brian Ruffell; David H Munn; Juan R Cubillos-Ruiz; Jose R Conejo-Garcia; Paulo C Rodriguez
Journal:  Immunity       Date:  2020-04-14       Impact factor: 31.745

6.  Critical role of the mTOR pathway in development and function of myeloid-derived suppressor cells in lal-/- mice.

Authors:  Xinchun Ding; Hong Du; Mervin C Yoder; Cong Yan
Journal:  Am J Pathol       Date:  2013-11-26       Impact factor: 4.307

7.  Adoptive transfer of IFN-γ-induced M-MDSCs promotes immune tolerance to allografts through iNOS pathway.

Authors:  Fan Yang; Yang Li; Weilong Zou; Yanan Xu; Hao Wang; Wei Wang; Yong Zhao
Journal:  Inflamm Res       Date:  2019-05-04       Impact factor: 4.575

8.  Immature myeloid cells are critical for enhancing bone fracture healing through angiogenic cascade.

Authors:  Seth Levy; Joseph M Feduska; Anandi Sawant; Shawn R Gilbert; Jonathan A Hensel; Selvarangan Ponnazhagan
Journal:  Bone       Date:  2016-09-21       Impact factor: 4.398

Review 9.  Immunotherapy for brain cancer: recent progress and future promise.

Authors:  Christopher M Jackson; Michael Lim; Charles G Drake
Journal:  Clin Cancer Res       Date:  2014-04-25       Impact factor: 12.531

10.  Myeloid-derived suppressor cells in the development of lung cancer.

Authors:  Myrna L Ortiz; Lily Lu; Indu Ramachandran; Dmitry I Gabrilovich
Journal:  Cancer Immunol Res       Date:  2013-10-18       Impact factor: 11.151

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.